Prostate cancer and novel pharmacological treatment options–what's new for 2022?
A Marchetti, E Tassinari, M Rosellini… - Expert Review of …, 2023 - Taylor & Francis
Introduction Androgen deprivation therapy (ADT) plus Androgen Receptor Target Agents
(ARTAs) or docetaxel are the actual standard of care in prostate cancer (PC). Several …
(ARTAs) or docetaxel are the actual standard of care in prostate cancer (PC). Several …
Second-line treatment options in metastatic castration-resistant prostate cancer after progression on first-line androgen-receptor targeting therapies: A systematic …
Objective To summarize and indirectly compare the efficacy and safety of different second-
line systematic therapies after first-line androgen-receptor targeting therapies (ARTs) for …
line systematic therapies after first-line androgen-receptor targeting therapies (ARTs) for …
Chronic convection-enhanced intratumoural delivery of chemotherapy for glioblastoma
In The Lancet Oncology, Eleonora F Spinazzi and colleagues1 present a first-in-human
study of chronic convection-enhanced delivery (CED) of chemotherapy to five patients with …
study of chronic convection-enhanced delivery (CED) of chemotherapy to five patients with …
Efficacy and safety of interventions for metastatic castration resistant prostate cancer (mCRPC) patients progressing on androgen receptor-axis-targeted (ARAT) …
K Yan, C Balijepalli, L Gullapalli, J Joshy… - Current Medical …, 2024 - Taylor & Francis
Background To review the literature to outline findings from clinical trials assessing
interventions for metastatic castration-resistant prostate cancer (mCRPC) in patients who …
interventions for metastatic castration-resistant prostate cancer (mCRPC) in patients who …
[PDF][PDF] Re: Continuous Enzalutamide After Progression of Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel (PRESIDE): An International …
T Habuchi - European Urology, 2023 - Elsevier
Concomitant treatment with androgen deprivation therapy (ADT) and one androgen receptor
axis–targeted (ARAT) agent, such as abiraterone acetate (AA), enzalutamide, or …
axis–targeted (ARAT) agent, such as abiraterone acetate (AA), enzalutamide, or …
Highlighting recent progress in the treatment of men with advanced prostate cancer
T Gourdin - Current Opinion in Oncology, 2024 - journals.lww.com
Highlighting recent progress in the treatment of men with ad... : Current Opinion in Oncology
Highlighting recent progress in the treatment of men with advanced prostate cancer …
Highlighting recent progress in the treatment of men with advanced prostate cancer …
Continuing enzalutamide with docetaxel in castration-resistant prostate cancer
M Shiota - The Lancet Oncology, 2022 - thelancet.com
Shutterstock. com benefit of combination therapy in mCRPC, and lifeprolonging drugs are
administered sequentially for patients with mCRPC. However, the potential ability of …
administered sequentially for patients with mCRPC. However, the potential ability of …